폐 약물전달 디바이스 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

Pulmonary Drug Delivery Devices Market (Product Type: Dry Powder Inhalers, Metered Dose Inhalers, and Nebulizers; Application: Asthma, COPD, and Cystic Fibrosis) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

US $ 5,795 ￦ 8,030,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795 ￦ 12,188,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795 ￦ 16,345,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

폐 약물전달 디바이스 시장 - 보고서의 범위

TMR의 세계 폐 약물전달 디바이스 시장에 대한 보고서는 과거와 현재의 성장 동향과 2023년부터 2031년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻을 수 있는 기회를 조사했습니다. 이 보고서는 2023년을 기준 연도 및 2031년을 예측 연도로 간주하여 2017년부터 2031년까지의 세계 폐 약물전달 디바이스 시장의 수익을 제공합니다. 이 보고서는 또한 2023년부터 2031년까지 세계 폐 약물전달 디바이스 시장의 복합 연간 성장률(CAGR%)을 제공합니다.

이 보고서는 광범위한 조사를 통해 작성되었습니다. KOL(Key Opinion Leader), 업계 리더 및 제조업체를 인터뷰하는 1차 조사 활동의 대부분을 분석가들이 수행했으며, 2차 조사에는 XX 시장을 이해하기 위해 주요 업체의 제품 문헌, 연례 보고서, 보도 자료 및 관련 문서 참조가 포함되었습니다.

시장 현황
2023년 시장 가치	372억 달러
2031년 시장 가치	550억 달러
CAGR	4.4%

이 보고서는 세계 폐 약물전달 디바이스 시장 경쟁 구도를 자세히 조사했습니다. 세계 폐 약물전달 디바이스 시장에서 활동하는 주요 기업을 파악할 수 있으며, 이들 각각은 다양한 속성 측면에서 프로파일링됩니다. 기업 프로파일, 재무 상태, 최근 동향 및 SWOT는 이 보고서에 소개된 세계 폐 약물전달 디바이스 시장 기업의 속성입니다.

목차

제1장 주요 요약

제2장 전제조건과 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

• 시장 세분화
• 개요
• 시장 역학
• 세계 시장 분석과 예측, 2023-2031년

제5장 주요 인사이트

• 파이프라인 분석
• 세계 주요 국가의 질병 유병률과 이환율
• COVID-19 팬데믹이 업계에 미치는 영향

제6장 시장 분석과 예측 : 제품 유형별

• 서론과 정의
• 주요 조사 결과/발전
• 시장 매출과 수량 예측 : 제품 유형별, 2023-2031
  • 드라이 파우더 흡입기
  • 정량 흡입기
  • 네뷸라이저
• 시장 매력도 : 제품 유형별

제7장 시장 분석과 예측 : 용도별

• 서론과 정의
• 주요 조사 결과/발전
• 시장 매출과 수량 예측 : 용도별, 2023-2031
  • 천식
  • COPD
  • 낭포성 섬유증
  • 기타
• 시장 매력도 : 용도별

제8장 세계 시장 분석과 예측 : 유통 채널별

• 서론과 정의
• 주요 조사 결과/발전
• 시장 매출과 수량 예측 : 유통 채널별, 2023-2031
  • 소매 약국
  • 병원 약국
  • E-Commerce
• 시장 매력도 : 유통 채널별

제9장 세계 시장 분석과 예측 : 지역별

• 주요 조사 결과
• 시장 매출과 수량 예측 : 지역별, 2023-2031
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카
• 시장 매력도 : 지역별

제10장 북미 시장 분석과 예측

제11장 유럽 시장 분석과 예측

제12장 아시아태평양 시장 분석과 예측

제13장 라틴아메리카 시장 분석과 예측

제14장 중동 및 아프리카 시장 분석과 예측

제15장 경쟁 구도

• 시장 기업--경쟁 매트릭스(기업 Tier 및 규모별)
• 시장 점유율 분석 : 기업별(2022년)
• 기업 개요
  • AstraZeneca Plc
  • Novartis AG
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline Plc
  • Merck &Co., Inc.
  • Teva Pharmaceutical Industries Ltd.

LSH

영문 목차

영문목차

Pulmonary Drug Delivery Devices Market - Scope of Report

TMR's report on the global pulmonary drug delivery devices market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global pulmonary drug delivery devices market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global pulmonary drug delivery devices market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the pulmonary drug delivery devices market.

Market Snapshot
Market Value in 2023	US$ 37.2 Bn
Market Value in 2031	US$ 55 Bn
CAGR	4.4%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global pulmonary drug delivery devices market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global pulmonary drug delivery devices market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global pulmonary drug delivery devices market.

The report delves into the competitive landscape of the global pulmonary drug delivery devices market. Key players operating in the global pulmonary drug delivery devices market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global pulmonary drug delivery devices market profiled in this report.

Key Questions Answered in Global pulmonary drug delivery devices Market Report:

• What is the sales/revenue generated by pulmonary drug delivery devices across all regions during the forecast period?
• What are the opportunities in the global pulmonary drug delivery devices market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Pulmonary Drug Delivery Devices Market - Research Objectives and Research Approach

The comprehensive report on the global pulmonary drug delivery devices market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global pulmonary drug delivery devices market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global pulmonary drug delivery devices market.

Table of Contents

1. Executive Summary

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Pulmonary Drug Delivery Devices Market

4. Market Overview

• 4.1. Market Segmentation
  • 4.1.1. Segment Definition
  • 4.1.2. Industry Evolution / Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Pulmonary Drug Delivery Devices Market Analysis and Forecast, 2023-2031

5. Key Insights

• 5.1. Pipeline Analysis
• 5.2. Disease Prevalence & Incidence Rate Globally With Key Countries
• 5.3. COVID-19 Pandemic Impact on Industry

6. Pulmonary Drug Delivery Devices Market Analysis and Forecast, by Product Type

• 6.1. Introduction and Definitions
• 6.2. Key Findings/Developments
• 6.3. Market Value & Volume Forecast, by Product Type, 2023-2031
  • 6.3.1. Dry Powder Inhalers
  • 6.3.2. Metered Dose Inhalers
  • 6.3.3. Nebulizers
• 6.4. Market Attractiveness, by Product Type

7. Pulmonary Drug Delivery Devices Market Analysis and Forecast, by Application

• 7.1. Introduction and Definitions
• 7.2. Key Findings/Developments
• 7.3. Market Value & Volume Forecast, by Application, 2023-2031
  • 7.3.1. Asthma
  • 7.3.2. COPD
  • 7.3.3. Cystic Fibrosis
  • 7.3.4. Others
• 7.4. Market Attractiveness, by Application

8. Global Pulmonary Drug Delivery Devices Market Analysis and Forecast, by Distribution Channel

• 8.1. Introduction and Definitions
• 8.2. Key Findings/Developments
• 8.3. Market Value & Volume Forecast, by Distribution Channel, 2023-2031
  • 8.3.1. Retail Pharmacies
  • 8.3.2. Hospital Pharmacies
  • 8.3.3. E-Commerce
• 8.4. Market Attractiveness, by Distribution Channel

9. Global Pulmonary Drug Delivery Devices Market Analysis and Forecast, by Region

• 9.1. Key Findings
• 9.2. Market Value & Volume Forecast, by Region, 2023-2031
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness, by Region

10. North America Pulmonary Drug Delivery Devices Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value & Volume Forecast, by Product Type, 2023-2031
  • 10.2.1. Dry Powder Inhalers
  • 10.2.2. Metered Dose Inhalers
  • 10.2.3. Nebulizers
• 10.3. Market Attractiveness, by Product Type
• 10.4. Market Value & Volume Forecast, by Application, 2023-2031
  • 10.4.1. Asthma
  • 10.4.2. COPD
  • 10.4.3. Cystic Fibrosis
  • 10.4.4. Others
• 10.5. Market Attractiveness, by Application
• 10.6. Market Value & Volume Forecast, by Distribution Channel, 2023-2031
  • 10.6.1. Retail Pharmacies
  • 10.6.2. Hospital Pharmacies
  • 10.6.3. E-Commerce
• 10.7. Market Attractiveness, by Distribution Channel
• 10.8. Market Value & Volume Forecast, by Country, 2023-2031
  • 10.8.1. U.S.
  • 10.8.2. Canada
• 10.9. Market Attractiveness Analysis
  • 10.9.1. By Product Type
  • 10.9.2. By Application
  • 10.9.3. By Distribution Channel
  • 10.9.4. By Country

11. Europe Pulmonary Drug Delivery Devices Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value & Volume Forecast, by Product Type, 2023-2031
  • 11.2.1. Dry Powder Inhalers
  • 11.2.2. Metered Dose Inhalers
  • 11.2.3. Nebulizers
• 11.3. Market Attractiveness, by Product Type
• 11.4. Market Value & Volume Forecast, by Application, 2023-2031
  • 11.4.1. Asthma
  • 11.4.2. COPD
  • 11.4.3. Cystic Fibrosis
  • 11.4.4. Others
• 11.5. Market Attractiveness, by Application
• 11.6. Market Value & Volume Forecast, by Distribution Channel, 2023-2031
  • 11.6.1. Retail Pharmacies
  • 11.6.2. Hospital Pharmacies
  • 11.6.3. E-Commerce
• 11.7. Market Attractiveness, by Distribution Channel
• 11.8. Market Value & Volume Forecast, by Country/Sub-region, 2023-2031
  • 11.8.1. Germany
  • 11.8.2. U.K.
  • 11.8.3. France
  • 11.8.4. Italy
  • 11.8.5. Spain
  • 11.8.6. Rest of Europe
• 11.9. Market Attractiveness Analysis
  • 11.9.1. By Product Type
  • 11.9.2. By Application
  • 11.9.3. By Distribution Channel
  • 11.9.4. By Country/Sub-region

12. Asia Pacific Pulmonary Drug Delivery Devices Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value & Volume Forecast, by Product Type, 2023-2031
  • 12.2.1. Dry Powder Inhalers
  • 12.2.2. Metered Dose Inhalers
  • 12.2.3. Nebulizers
• 12.3. Market Attractiveness, by Product Type
• 12.4. Market Value & Volume Forecast, by Application, 2023-2031
  • 12.4.1. Asthma
  • 12.4.2. COPD
  • 12.4.3. Cystic Fibrosis
  • 12.4.4. Others
• 12.5. Market Attractiveness, by Application
• 12.6. Market Value & Volume Forecast, by Distribution Channel, 2023-2031
  • 12.6.1. Retail Pharmacies
  • 12.6.2. Hospital Pharmacies
  • 12.6.3. E-Commerce
• 12.7. Market Attractiveness, by Distribution Channel
• 12.8. Market Value & Volume Forecast, by Country/Sub-region, 2023-2031
  • 12.8.1. China
  • 12.8.2. Japan
  • 12.8.3. India
  • 12.8.4. Australia & New Zealand
  • 12.8.5. Rest of Asia Pacific
• 12.9. Market Attractiveness Analysis
  • 12.9.1. By Product Type
  • 12.9.2. By Application
  • 12.9.3. By Distribution Channel
  • 12.9.4. By Country/Sub-region

13. Latin America Pulmonary Drug Delivery Devices Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value & Volume Forecast, by Product Type, 2023-2031
  • 13.2.1. Dry Powder Inhalers
  • 13.2.2. Metered Dose Inhalers
  • 13.2.3. Nebulizers
• 13.3. Market Attractiveness, by Product Type
• 13.4. Market Value & Volume Forecast, by Application, 2023-2031
  • 13.4.1. Asthma
  • 13.4.2. COPD
  • 13.4.3. Cystic Fibrosis
  • 13.4.4. Others
• 13.5. Market Attractiveness, by Application
• 13.6. Market Value & Volume Forecast, by Distribution Channel, 2023-2031
  • 13.6.1. Retail Pharmacies
  • 13.6.2. Hospital Pharmacies
  • 13.6.3. E-Commerce
• 13.7. Market Attractiveness, by Distribution Channel
• 13.8. Market Value & Volume Forecast, by Country/Sub-region, 2023-2031
  • 13.8.1. Brazil
  • 13.8.2. Mexico
  • 13.8.3. Rest of Latin America
• 13.9. Market Attractiveness Analysis
  • 13.9.1. By Product Type
  • 13.9.2. By Application
  • 13.9.3. By Distribution Channel
  • 13.9.4. By Country/Sub-region

14. Middle East & Africa Pulmonary Drug Delivery Devices Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value & Volume Forecast, by Product Type, 2023-2031
  • 14.2.1. Dry Powder Inhalers
  • 14.2.2. Metered Dose Inhalers
  • 14.2.3. Nebulizers
• 14.3. Market Attractiveness, by Product Type
• 14.4. Market Value & Volume Forecast, by Application, 2023-2031
  • 14.4.1. Asthma
  • 14.4.2. COPD
  • 14.4.3. Cystic Fibrosis
  • 14.4.4. Others
• 14.5. Market Attractiveness, by Application
• 14.6. Market Value & Volume Forecast, by Distribution Channel, 2023-2031
  • 14.6.1. Retail Pharmacies
  • 14.6.2. Hospital Pharmacies
  • 14.6.3. E-Commerce
• 14.7. Market Attractiveness, by Distribution Channel
• 14.8. Market Value & Volume Forecast, by Country/Sub-region, 2023-2031
  • 14.8.1. GCC Countries
  • 14.8.2. South Africa
  • 14.8.3. Rest of Middle East & Africa
• 14.9. Market Attractiveness Analysis
  • 14.9.1. By Product Type
  • 14.9.2. By Application
  • 14.9.3. By Distribution Channel
  • 14.9.4. By Country/Sub-region

15. Competition Landscape

• 15.1. Market Player - Competition Matrix (By Tier and Size of Companies)
• 15.2. Market Share Analysis, by Company (2022)
• 15.3. Company Profiles
  • 15.3.1. AstraZeneca Plc
    • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.1.2. Product Type Portfolio
    • 15.3.1.3. Financial Overview
    • 15.3.1.4. SWOT Analysis
    • 15.3.1.5. Strategic Overview
  • 15.3.2. Novartis AG
    • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.2.2. Product Type Portfolio
    • 15.3.2.3. Financial Overview
    • 15.3.2.4. SWOT Analysis
    • 15.3.2.5. Strategic Overview
  • 15.3.3. Boehringer Ingelheim GmbH
    • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.3.2. Product Type Portfolio
    • 15.3.3.3. Financial Overview
    • 15.3.3.4. SWOT Analysis
    • 15.3.3.5. Strategic Overview
  • 15.3.4. GlaxoSmithKline Plc
    • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.4.2. Product Type Portfolio
    • 15.3.4.3. Financial Overview
    • 15.3.4.4. SWOT Analysis
    • 15.3.4.5. Strategic Overview
  • 15.3.5. Merck & Co., Inc.
    • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.5.2. Product Type Portfolio
    • 15.3.5.3. Financial Overview
    • 15.3.5.4. SWOT Analysis
    • 15.3.5.5. Strategic Overview
  • 15.3.6. Teva Pharmaceutical Industries Ltd.
    • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.6.2. Product Type Portfolio
    • 15.3.6.3. Financial Overview
    • 15.3.6.4. SWOT Analysis
    • 15.3.6.5. Strategic Overview

관련자료